Published in J Immunol on June 01, 2002
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73
Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity (2008) 4.67
Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2009) 3.46
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 3.19
Biology of interleukin-22. Semin Immunopathol (2010) 2.92
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med (2009) 2.28
A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol (2007) 2.16
Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther (2007) 1.83
IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol (2012) 1.68
Interleukin-22: immunobiology and pathology. Annu Rev Immunol (2015) 1.60
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol (2010) 1.53
Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A (2009) 1.44
Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One (2012) 1.37
Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol (2011) 1.33
Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res (2010) 1.32
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun (2008) 1.26
IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol Gastrointest Liver Physiol (2009) 1.24
IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol (2012) 1.22
Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia (2008) 1.16
Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics (2010) 1.15
Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun (2009) 1.14
Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med (2008) 1.14
Dectin-1-dependent interleukin-22 contributes to early innate lung defense against Aspergillus fumigatus. Infect Immun (2011) 1.13
Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol (2012) 1.07
Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect Immun (2007) 1.06
Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc Natl Acad Sci U S A (2012) 1.03
Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev (2010) 1.03
Interleukin-24 and its receptors. Immunology (2005) 1.02
Long-range regulation of cytokine gene expression. Curr Opin Immunol (2008) 1.01
IL-22 signaling contributes to West Nile encephalitis pathogenesis. PLoS One (2012) 1.01
Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome. PLoS One (2012) 0.99
The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology (2014) 0.98
The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther (2010) 0.98
Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98
New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod Rheumatol (2008) 0.98
Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet (2008) 0.96
IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Res (2012) 0.95
A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc Natl Acad Sci U S A (2009) 0.94
IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol (2014) 0.94
IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One (2015) 0.92
Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol (2013) 0.92
Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers (2013) 0.91
IL-1β promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes. J Immunol (2014) 0.91
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs (2010) 0.91
IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. J Cancer (2012) 0.91
Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum (2013) 0.90
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Exp Dermatol (2010) 0.90
Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res (2014) 0.89
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res (2008) 0.89
Conventional NK cells can produce IL-22 and promote host defense in Klebsiella pneumoniae pneumonia. J Immunol (2014) 0.89
Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. BMC Microbiol (2005) 0.88
Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis. Mediators Inflamm (2013) 0.87
Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS One (2007) 0.87
Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV). J Cell Physiol (2014) 0.86
Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169. Virus Res (2007) 0.86
Melatonin attenuates acute pancreatitis-associated lung injury in rats by modulating interleukin 22. World J Gastroenterol (2012) 0.85
Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol (2013) 0.85
Innate lymphoid cells and cytokines of the novel subtypes of helper T cells in asthma. Asia Pac Allergy (2014) 0.85
Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis. J Infect Dis (2013) 0.85
Comparative study and expression analysis of the interferon gamma gene locus cytokines in Xenopus tropicalis. Immunogenetics (2008) 0.85
In vivo consequence of vitamin C insufficiency in liver injury: vitamin C ameliorates T-cell-mediated acute liver injury in gulo(-/-) mice. Antioxid Redox Signal (2013) 0.85
Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia (2014) 0.84
Association of the IL-10 gene family locus on chromosome 1 with juvenile idiopathic arthritis (JIA). PLoS One (2012) 0.84
Interleukin-19 in breast cancer. Clin Dev Immunol (2013) 0.84
The other T helper cells in asthma pathogenesis. J Allergy (Cairo) (2010) 0.84
Anti-inflammatory effects of interleukin-19 in vascular disease. Int J Inflam (2012) 0.84
The DNA-binding factor Ctcf critically controls gene expression in macrophages. Cell Mol Immunol (2013) 0.84
IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med (2008) 0.84
Interleukin-22 produced by alveolar macrophages during activation of the innate immune response. Inflamm Res (2013) 0.84
An integrative computational systems biology approach identifies differentially regulated dynamic transcriptome signatures which drive the initiation of human T helper cell differentiation. BMC Genomics (2012) 0.83
The cationic cytokine IL-26 differentially modulates virus infection in culture. PLoS One (2013) 0.82
Increased expression of IL-22 is associated with disease activity in Behcet's disease. PLoS One (2013) 0.82
The role of macrophage IL-10/innate IFN interplay during virus-induced asthma. Rev Med Virol (2014) 0.82
Interleukin-19 in fetal systemic inflammation. J Matern Fetal Neonatal Med (2012) 0.81
IL-22 secreted by decidual stromal cells and NK cells promotes the survival of human trophoblasts. Int J Clin Exp Pathol (2013) 0.81
Biological and pathological activities of interleukin-22. J Mol Med (Berl) (2016) 0.80
The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol (2014) 0.80
STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease? J Interferon Cytokine Res (2015) 0.80
First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis. PLoS One (2015) 0.80
Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation (2015) 0.80
Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation. J Mol Cell Biol (2010) 0.80
The Role of Interleukin-22 and Its Receptor in the Development and Pathogenesis of Experimental Autoimmune Uveitis. PLoS One (2016) 0.80
Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity. Clin Exp Immunol (2015) 0.80
The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Res Ther (2016) 0.79
Natural killer (NK) and NK-like cells at mucosal epithelia: Mediators of anti-microbial defense and maintenance of tissue integrity. Eur J Microbiol Immunol (Bp) (2011) 0.79
The peripheral blood transcriptome reflects variations in immunity traits in swine: towards the identification of biomarkers. BMC Genomics (2013) 0.79
Interleukin-19 impairment in active Crohn's disease patients. PLoS One (2014) 0.79
Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79
Cytokine and chemokine responses to helminth and protozoan parasites and to fungus and mite allergens in neonates, children, adults, and the elderly. Immun Ageing (2013) 0.79
Interleukin-19 acts as a negative autocrine regulator of activated microglia. PLoS One (2015) 0.79
Role of interleukin-22 in inflammatory bowel disease. World J Gastroenterol (2014) 0.78
A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression. Br J Cancer (2012) 0.78
Detection of interleukin-19 mRNA in C57BL/6 mice astroglial cells and brain cortex. Basic Clin Neurosci (2014) 0.78
Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells. Int J Cancer (2011) 0.77
IL-22-Expressing Murine Lymphocytes Display Plasticity and Pathogenicity in Reporter Mice. Front Immunol (2016) 0.77
Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov (2011) 22.33
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
IL-22 increases the innate immunity of tissues. Immunity (2004) 8.30
Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther (2002) 5.43
IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol (2006) 4.88
Biology of interleukin-22. Semin Immunopathol (2010) 2.92
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev (2006) 2.73
Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med (2009) 2.28
IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol (2007) 1.80
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) (2009) 1.76
Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood (2003) 1.76
Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev (2010) 1.76
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A (2003) 1.71
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol (2009) 1.53
Crowd sourcing in drug discovery. Nat Rev Drug Discov (2011) 1.51
Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol (2008) 1.50
IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev (2010) 1.45
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41
Glucocorticoid therapy-induced skin atrophy. Exp Dermatol (2006) 1.40
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood (2002) 1.40
Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol (2007) 1.39
Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med (2011) 1.38
Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol (2007) 1.32
Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med (2005) 1.31
Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 1.19
Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med (2008) 1.14
Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol (2004) 1.14
Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy (2004) 1.12
IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med (2013) 1.09
Differential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis. Int Immunol (2009) 1.09
Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem (2003) 1.06
Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol (2010) 1.04
Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity (2013) 1.03
Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol (2009) 1.02
Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol (2007) 1.02
Interleukin-22: implications for liver ischemia-reperfusion injury. Transplantation (2012) 1.02
An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 1.01
Interleukin-10 and articular cartilage: experimental therapeutical approaches in cartilage disorders. Curr Gene Ther (2009) 0.99
Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol (2004) 0.98
Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr Opin Investig Drugs (2005) 0.96
Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol (2007) 0.96
A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. J Invest Dermatol (2002) 0.94
TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol (2006) 0.93
Immunomodulation by a novel, dissociated Vitamin D analogue. Exp Dermatol (2009) 0.92
Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol (2006) 0.92
What makes a good drug target? Drug Discov Today (2011) 0.92
Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol (2011) 0.91
Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy (2004) 0.91
Role of fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity. Trends Immunol (2003) 0.90
Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit Care Med (2007) 0.90
Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res (2005) 0.90
IL-10 protects monocytes and macrophages from complement-mediated lysis. J Leukoc Biol (2009) 0.90
Interleukin-28 and interleukin-29: novel regulators of skin biology. J Interferon Cytokine Res (2010) 0.88
Cytokine and anticytokine therapy in dermatology. Expert Opin Biol Ther (2003) 0.87
Administration of IL-23 engages innate and adaptive immune mechanisms during fungal infection. Int Immunol (2009) 0.87
Techniques: species' finest blend--humanized mouse models in inflammatory skin disease research. Trends Pharmacol Sci (2004) 0.86
CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity. Exp Dermatol (2008) 0.86
Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res (2002) 0.86
Targeting leukocyte trafficking to inflamed skin: still an attractive therapeutic approach? Exp Dermatol (2007) 0.85
Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs (2006) 0.85
Antibody epitope mapping using SPOT peptide arrays. Methods Mol Biol (2009) 0.84
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol (2011) 0.84
Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol (2011) 0.82
Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol (2002) 0.82
[Founding the new German Skin Research Center]. J Dtsch Dermatol Ges (2007) 0.81
Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. Drug Discov Today (2010) 0.80
The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy (2004) 0.80
Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J Leukoc Biol (2008) 0.80
Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis. Exp Dermatol (2011) 0.80
Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol (2007) 0.80
Selectin and selectin ligand binding: a bittersweet attraction. J Clin Invest (2003) 0.80
Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol (2009) 0.79
Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol (2003) 0.79
A simple assay to measure phagocytosis of live bacteria. Clin Chem (2008) 0.78
Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges (2013) 0.78
RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genes. Cell Commun Signal (2008) 0.78
What makes a good drug target? Drug Discov Today (2011) 0.78
Animal models of T-cell-mediated skin diseases. Bioessays (2004) 0.77
Ultraviolet B radiation-mediated inhibition of interferon-gamma-induced keratinocyte activation is independent of interleukin-10 and other soluble mediators but associated with enhanced intracellular suppressors of cytokine-signaling expression. J Invest Dermatol (2003) 0.77